Competitor Shortages Allow Amphastar To Deliver ‘Strongest Quarter Yet’

Pending Launches Expected To Drive Future Growth

After shortages at competitor companies opened up gaps in the market Amphastar was able to step in to fill the void, leading to its most successful quarter yet with net revenues of $135m.

Gold medal bearing the number one, winner's medal
Amphastar secured GAAP net income of $33.9m during Q4 • Source: Shutterstock

Amphastar has reported its “strongest quarter yet”, as competitor shortages led to outsized sales performances for glucagon while growth trends continued for epinephrine and Primatene Mist, which maintained solid market shares.

Jack Zhang, Amphastar's president and CEO, said: “Looking ahead to 2023, we anticipate launching multiple new products to continue driving...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business